NEW YORK -- Elan
reached a $1 billion agreement in which Elan will buy 21% of royalties that Theravance receives from GlaxoSmithKline
for four respiratory drugs.
The deal includes Breo Ellipta, a new treatment for chronic obstructive pulmonary disease that received approval from the Food and Drug Administration last week.
4 Stocks Spiking on Big Volume
Take-Two Interactive Software
is expected by analysts on Monday to post fiscal fourth-quarter earnings of 23 cents a share on revenue of $280.1 million.
Cereal company Post Holdings
is expected by Wall Street to report fiscal second-quarter earnings of 27 cents a share on revenue of $255.7 million.
is forecast to post first-quarter earnings of 43 cents a share on sales of $582 million.
is expected by analysts on Monday to post a first-quarter loss of 19 cents a share.
5 Stocks Poised to Break Out
-- Written by Joseph Woelfel
>To contact the writer of this article, click here: Joseph Woelfel
>To submit a news tip, send an email to: email@example.com.